TEVA SETTLES PATENT CHALLENGE OF GSK DRUGS

NOVEMBER 01, 2007

Teva Pharmaceutical Industries Ltd has resolved its patent dispute with GlaxoSmithKline (GSK) via a settlement that will allow the Israel-based generic drug maker to enter the US market with its generic versions of 3 GSK diabetes drugs: Avandia (rosiglitazone maleate), Avandamet (rosiglitazone maleate and metformin HCl), and Avandaryl (rosiglitazone maleate and glimepiride) oral tablets. Although details of the settlement were held confidential by both parties, it was disclosed that Teva could begin US marketing of the GSK drugs late in the first quarter of 2012. GSK filed several lawsuits challenging Teva?s plans to market generic versions of its drugs, and a trial in federal court had been scheduled to begin in August.




SHARE THIS SHARE THIS
0

Conference Coverage from ASHP Summer 2017 

Four years after they first launched the Summer Meetings in Minneapolis, Minn., the ASHP 2017 Summer Meetings and Exhibition was in Minneapolis once again.  

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.